(CDXC) shares traded as high as $18.74 recently with solid volume

[Health Master]

(CDXC) ChromaDex, Key products, Tru Niagen and Niagen, have shown promising growth with diminishing impact of COVID-19 following availability of vaccines, prospect of these products are likely to get boosted. Chromadex Corp Achieves Reduction In Recovery In Mild To Moderate Covid-19 patients Administered With Combined Metabolic Activators: Raises $25 Million.